Expected Impact

PRISM 2 outcomes are expected to have a positive impact on public health in general by improving European citizens’ mental health and well-being, reducing the stigma of neuropsychiatric disorders, and advancing health technology assessment, clinical practice, and regulatory guidelines. In addition, PRISM 2 will improve the drug discovery and development process by identifying and valorising novel biomarkers and potential drug targets, maximise the public-private partnership value by harnessing support from different stakeholders, and contribute to industrial prosperity and leadership of the European Union (EU), including small and medium-sized enterprises (SMEs).

Expected impact: Expected real-life effects by PRISM 2’s innovative transdiagnostic approach.